General Session I: A Primer on the Clinical Application of Molecular Biomarkers

• Bioinformatics: prognostic, predictive, and pharmacodynamic biomarkers - Michael W. Kattan, MD
• Genetics vs. cancer genomics - Katherine Hoadley, PhD
• Proteomics - Towia Libermann, PhD
• Review of methodologies for biomarker testing (IHC, FISH, DNA sequencing, etc) - Mark Sausen PhD

Keynote Presentation: Exploring Molecular Pathways in Cancer - Alex Adjei, MD, PhD

Break

General Session II: What’s New in Cancer Biomarker Research

• In clinical development on the verge of commercialization - Jerald Radich, MD
• In preclinical development: the mouse avatar model for translational cancer research - Philip C. Mack, PhD

• Melanoma - Sanjiv S. Agarwala, MD
• NSCLC - Mark A. Socinski, MD
• Breast cancer - Joyce O'Shaughnessy, MD
• Colorectal and other GI cancers - William M. Grady, MD

Keynote Session:  Targeting Genetic Drivers in Premalignancy - Scott M. Lippman, MD

• AML/CML - Jorge Cortes, MD
• Multiple myeloma - Keith Stewart, MB, ChB
• CLL - Michael Keating, MD
• Lymphoma - Joseph Connors, MD

Keynote Presentation: An Industry Perspective on the Use of Biomarkers in Cancer:
How are They Really Used? -

Roman Yelensky, PhD

General Session V: Molecular Biomarkers for the Early Detection of Cancer

• Colorectal Cancer - Hemant K. Roy, MD
• Lung Cancer - Avi Spira MD. MSc
• Breast Cancer - Susan Neuhausen, PhD

Break

General Session VI: Regulatory and Economic Aspects of Precision Medicine

• The Regulatory perspective - Andrew Stainthorpe, PhD
• The payers perspective - Michael Kolodziej, MD

 Poster Presentation - Winner of Best Poster Abstract, GBC

"Meet the Experts" Reception - A parting Opportunity for Informal communication and Networking, and viewing of posters and exhibits

General Session I: Clinical Presentations of Cutaneous Malignancies

• Melanoma: What's new from the Dermatology Perspective - Suraj Venna, MD
• Basal cell carcinoma and Gorlin syndrome - Cristopher Bichakjian, MD
• Cutaneous T-Cell lymphoma, MF, Sezary syndrome - Joan Guitart, MD
• Merkel cell tumor - Shailender Bhatia, MD

General Session II: Understanding the Molecular Biology of Cutaneous Malignancies: Application to Clinical Practice

• Melanoma - Roger Lo, MD, PhD
• Basal cell carcinoma - Steven A. Nelson, MD
• Cutaneous T-Cell lymphoma - Joan Guitart, MD
• Merkel cell tumor - Jaehyuk Choi, MD, PhD

Break

General Session III: Surgical and Locoregional Therapies

• Surgical Treatement of melanoma - Merrick I Ross, MD
• Intralesional therapy of Melanoma - Sanjiv S. Agarwala, MD
• Moh's surgery for melanoma - David G. Brodland, MD

General Session IV: Current Approaches to Therapy—Case Studies in Malignant Melanoma

• Approach to the BRAF + patient - Grant McArthur, PhD
• Management of brain Metastases -John Thompson, MD
• Melanoma follow up: a dermatologist's perspective - Mohammed Kashani-Sabet, MD
• Manifestations and Management of cutaneous toxicities of Melanoma therapy - Mario E. Lacouture, MD

General Session V: Current Approaches to Therapy—Case Studies in Non-Melanoma Cutaneous Malignancies

• Basal cell carcinoma - Karl Lewis, MD
• Cutaneous T-Cell lymphoma - Madeleine Duvic, MD
• Merkel cell tumors - Manish Thakuria, MD

General Session VI: Emerging Therapies in Advanced Melanoma

• Adjuvant therapy: the global perspective - Vernon Sondak, MD
• New Treatment Algorithms: current status of immunotherapy in melanoma - Steven O'Day MD, PhD
• Emerging vaccines for advanced melanoma: a role for T-Vec and Immunopulse - Robert H.I Andtbacka, MD

General Session VII: Emerging Therapies in Advanced Non-Melanoma Cutaneous Malignancies

• Basal cell carcinoma - Aleksander Sekulic, MD, PhD
• Cutaneous T-cell Lymphoma - Larisa Geskin, MD
• Merkel cell cancer - Paul Nghiem MD, PhD

General Session VIII: Advances in the Prevention and Early Detection of Cutaneous Malignancies

• Melanoma - Axel Hauschild, MD
• Merkel Cell Cancer - Paul Nghiem, MD, PhD